Biospecimens and biorepositories for the community pathologist

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 6, 2012, Pages 668-678

  Dash, Rajesh C ^a   Robb, James A ^b   Booker, David L ^c   Foo, Wen Chi ^a   Witte, David L ^d   Bry, Lynn ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Department of Pathology   (United States)

^d Community Pathology Consultants ^*  (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMMUNITY MEDICINE; HEALTH CARE QUALITY; HUMAN; LABORATORY DIAGNOSIS; METHODOLOGY; PATHOLOGY; PERSONALIZED MEDICINE; STANDARD;

COMMUNITY MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; PATHOLOGY; QUALITY OF HEALTH CARE; SPECIMEN HANDLING;

EID: 84864261263     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0274-SO     Document Type: Article

References (21)

1. Health Insurance Portability and Accountability Act of 1996, Public Law 104-191 with revision, 42 USC §1320d-9 (2010).
2. National Institutes of Health. National Institute of Health Code of Federal Regulations, Title 45, Part 46, Human Subjects Research. http://ohsr.od.nih.gov/ guidelines/45cfr46.html. Published June 23, 2005. Accessed July 24, 2011.
3. College of American Pathologists. ER/PgR guideline and resources. http://www.cap.org/apps/cap.portaR-nfpb =true&cntvwrPtlt-actionOverride= %2Fportlets %2FcontentViewer%2Fshow&-windowLabel= cntvwrPtlt&cntvwrPtlt%7BactionForm.contentReference%7D=committees%2 Fpgr-index.html&-state=maximized&-pageLabel=cntvwr. Updated April 18, 2011. Accessed July 24, 2011.
4. Fitzgibbons PL, Murphy DA, Hammond ME, Allred DC, Valenstein PN. Recommendations for validating estrogen and progesterone receptor immuno-histochemistry assays. Arch Pathol Lab Med. 2010;134(6):930-935.
5. Institute CaLS. Quality Assurane for Design Control and Implementation of Immunohistochemistry Assays; Approved Guideline. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
6. RNAlater tissue collection: RNA stabilization solution. In: Biosystems A, ed: Ambion:1-12. http://www.ambion.com/catalog/ProdGrp.htmRfkProdGrp5 51. Accessed July 24, 2011.
7. Srinivasan M, Sedmak D, Jewell S. Effect offixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol. 2002;161(6):1961-1971. (Pubitemid 35434840)
8. Vincek V, Nassiri M, Nadji M, Morales AR. A tissue fixative that protects macromolecules (DNA, RNA, and protein) and histomorphology in clinical samples. Lab Invest. 2003;83(10):1427-1435. (Pubitemid 37267826)
9. Paavilainen L, Edvinsson A, Asplund A, et al. The impact of tissue fixatives on morphology and antibody-based protein profiling in tissues and cells. J Histochem Cytochem. 2010;58(3):237-246.
10. National Cancer Institute. Terminology resources: NCI Enterprise Vocabulary Services (EVS), dictionaries, FedMed, FDA, CDISC, and NCPDP terminology. CDISC terminology. http://www.cancer.gov/cancertopics/ cancerlibrary/ terminologyresources/cdisc. Accessed July 24, 2011.
11. College of American Pathologists. Cancer protocols and checklists. http:// www.cap.org/apps/cap.portal?-nfpb=true&cntvwrPtlt-actionOverride=/ portlets/ contentViewer/show&-windowLabel= cntvwrPtlt&cntvwrPtlt%7BactionForm. contentReference%7D=committees/cancer/ cancer-protocols/protocols-index. html&-pageLabel=cntvwr. Updated July 28, 2011. Accessed July 28, 2011.
12. De-Idata. De-Idata Health Data Safety software. http://www.de-idata.com/. Accessed July 24, 2011.
13. National Centers for Biomedical Computing. i2b2: informatics for integrating biology to the bedside. https://www.i2b2.org/. Accessed July 24, 2011.
14. Petrie K, Zelent A, Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol. 2009;16(2):84-91.
15. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol. 2010;28(31): 4769-4777.
16. Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte P. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breastcancer. CancerTreat Rev. 2010;36(suppl 3):S62-S66.
17. Hart JE, Jeon CY, Ivers LC, et al. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr. 2010;54(2):167-1 79.
18. Breccia M, Efficace F, Alimena G. Imatinib treatment in chronic myelogenous leukemia: what have we learned so far? Cancer Lett. 2011; 300(2):115-121.
19. Bronte G, Rizzo S, La Paglia L, et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev. 2010;36(suppl 3):S21-S29.
20. Márquez-Rodas I, Martín Algarra S, Avilés Izquierdo JA, Custodio Cabello S, Martín M. A new era in the treatment of melanoma: from biology to clinical practice. Clin Transl Oncol. 2011;13(11):787-792.
21. Croxtall JD, McKeage K. Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs. 2010;70(17):2259-2267.